Literature DB >> 24360562

The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs.

Emily R Jackson1, Géraldine San Jose1, Robert C Brothers1, Emma K Edelstein1, Zachary Sheldon1, Amanda Haymond2, Chinchu Johny2, Helena I Boshoff3, Robin D Couch2, Cynthia S Dowd4.   

Abstract

Inhibition of the nonmevalonate pathway (NMP) of isoprene biosynthesis has been examined as a source of new antibiotics with novel mechanisms of action. Dxr is the best studied of the NMP enzymes and several reports have described potent Dxr inhibitors. Many of these compounds are structurally related to natural products fosmidomycin and FR900098, each bearing retrohydroxamate and phosphonate groups. We synthesized a series of compounds with two to five methylene units separating these groups to examine what linker length was optimal and tested for inhibition against Mtb Dxr. We synthesized ethyl and pivaloyl esters of these compounds to increase lipophilicity and improve inhibition of Mtb growth. Our results show that propyl or propenyl linker chains are optimal. Propenyl analog 22 has an IC50 of 1.07 μM against Mtb Dxr. The pivaloyl ester of 22, compound 26, has an MIC of 9.4 μg/mL, representing a significant improvement in antitubercular potency in this class of compounds.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic; Dxr; Mycobacterium tuberculosis; Nonmevalonate pathway

Mesh:

Substances:

Year:  2013        PMID: 24360562      PMCID: PMC3927493          DOI: 10.1016/j.bmcl.2013.11.067

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

1.  Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity.

Authors:  A Reichenberg; J Wiesner; C Weidemeyer; E Dreiseidler; S Sanderbrand; B Altincicek; E Beck; M Schlitzer; H Jomaa
Journal:  Bioorg Med Chem Lett       Date:  2001-03-26       Impact factor: 2.823

Review 2.  Prospects for tuberculosis elimination.

Authors:  Christopher Dye; Philippe Glaziou; Katherine Floyd; Mario Raviglione
Journal:  Annu Rev Public Health       Date:  2012-12-14       Impact factor: 21.981

3.  Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

Authors:  Mounir Andaloussi; Lena M Henriksson; Anna Więckowska; Martin Lindh; Christofer Björkelid; Anna M Larsson; Surisetti Suresh; Harini Iyer; Bachally R Srinivasa; Terese Bergfors; Torsten Unge; Sherry L Mowbray; Mats Larhed; T Alwyn Jones; Anders Karlén
Journal:  J Med Chem       Date:  2011-07-01       Impact factor: 7.446

4.  Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity.

Authors:  Regina Ortmann; Jochen Wiesner; Armin Reichenberg; Dajana Henschker; Ewald Beck; Hassan Jomaa; Martin Schlitzer
Journal:  Arch Pharm (Weinheim)       Date:  2005-07       Impact factor: 3.751

Review 5.  Biochemistry of the non-mevalonate isoprenoid pathway.

Authors:  Tobias Gräwert; Michael Groll; Felix Rohdich; Adelbert Bacher; Wolfgang Eisenreich
Journal:  Cell Mol Life Sci       Date:  2011-07-09       Impact factor: 9.261

6.  Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.

Authors:  Eugene Uh; Emily R Jackson; Géraldine San Jose; Marcus Maddox; Robin E Lee; Richard E Lee; Helena I Boshoff; Cynthia S Dowd
Journal:  Bioorg Med Chem Lett       Date:  2011-10-05       Impact factor: 2.823

7.  Studies on phosphonic acid antibiotics. IV. Synthesis and antibacterial activity of analogs of 3-(N-acetyl-N-hydroxyamino)-propylphosphonic acid (FR-900098).

Authors:  K Hemmi; H Takeno; M Hashimoto; T Kamiya
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-01       Impact factor: 1.645

8.  In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic.

Authors:  Y Mine; T Kamimura; S Nonoyama; M Nishida; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1980-01       Impact factor: 2.649

9.  Design of Potential Bisubstrate Inhibitors against Mycobacterium tuberculosis (Mtb) 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase (Dxr)-Evidence of a Novel Binding Mode.

Authors:  Géraldine San Jose; Emily R Jackson; Eugene Uh; Chinchu Johny; Amanda Haymond; Lindsay Lundberg; Chelsea Pinkham; Kylene Kehn-Hall; Helena I Boshoff; Robin D Couch; Cynthia S Dowd
Journal:  Medchemcomm       Date:  2013-07-01       Impact factor: 3.597

10.  Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.

Authors:  Amanda C Brown; Tanya Parish
Journal:  BMC Microbiol       Date:  2008-05-20       Impact factor: 3.605

View more
  6 in total

Review 1.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

2.  MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.

Authors:  Xu Wang; Rachel L Edwards; Haley Ball; Claire Johnson; Amanda Haymond; Misgina Girma; Michelle Manikkam; Robert C Brothers; Kyle T McKay; Stacy D Arnett; Damon M Osbourn; Sophie Alvarez; Helena I Boshoff; Marvin J Meyers; Robin D Couch; Audrey R Odom John; Cynthia S Dowd
Journal:  J Med Chem       Date:  2018-09-24       Impact factor: 7.446

3.  Phosphoryl Prodrugs: Characteristics to Improve Drug Development.

Authors:  Samuel A Kirby; Cynthia S Dowd
Journal:  Med Chem Res       Date:  2021-07-23       Impact factor: 2.351

4.  Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.

Authors:  Géraldine San Jose; Emily R Jackson; Amanda Haymond; Chinchu Johny; Rachel L Edwards; Xu Wang; R Carl Brothers; Emma K Edelstein; Audrey R Odom; Helena I Boshoff; Robin D Couch; Cynthia S Dowd
Journal:  ACS Infect Dis       Date:  2016-10-12       Impact factor: 5.084

5.  MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis.

Authors:  Rachel L Edwards; Robert C Brothers; Xu Wang; Maxim I Maron; Peter D Ziniel; Patricia S Tsang; Thomas E Kraft; Paul W Hruz; Kim C Williamson; Cynthia S Dowd; Audrey R Odom John
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

6.  Potent, specific MEPicides for treatment of zoonotic staphylococci.

Authors:  Rachel L Edwards; Isabel Heueck; Soon Goo Lee; Ishaan T Shah; Justin J Miller; Andrew J Jezewski; Marwa O Mikati; Xu Wang; Robert C Brothers; Kenneth M Heidel; Damon M Osbourn; Carey-Ann D Burnham; Sophie Alvarez; Stephanie A Fritz; Cynthia S Dowd; Joseph M Jez; Audrey R Odom John
Journal:  PLoS Pathog       Date:  2020-06-04       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.